Sponsors (10)
Requires rapid manufacturer notification to FDA, immediate consultation, data sharing, and FDA reporting to improve infant formula safety and supply resiliency.
Official title: Improve the safety of infant formula through testing of infant formula for microorganisms, and for other purposes.
Introduced January 28, 2025 by Gary C. Peters · Last progress May 4, 2026
The bill increases reporting, transparency, and FDA powers to speed investigations and prevent contaminated infant formula from reaching babies—improving safety and shortage monitoring—at the cost of higher compliance burdens and proprietary risk for manufacturers, potential short‑term supply disruptions, and additional strain on FDA resources (and possibly taxpayer funding).
Parents and infants: Faster mandatory reporting (within 1 business day), required provision of isolates/whole‑genome data, and FDA confirmation timelines shorten investigations and reduce how long potentially contaminated formula stays in distribution.
Public health and families: FDA's authority to consult, require cessation of distribution, and order disposal of affected product helps stop wider outbreaks and protect vulnerable infants.
Parents and oversight bodies: Regular transparency and reporting (initial progress, periodic supply reports, quarterly updates for five years, and 1/3/5‑year reviews) improves visibility into formula safety and supply conditions.
FDA and other agencies: Tight timelines and expanded reporting increase workload and could strain FDA resources, divert staff from inspections, and lead to rushed or inconsistent determinations.
Manufacturers (especially smaller firms): Stricter rapid‑reporting, required sample/data sharing, disposal duties, and frequent supply‑chain reporting raise compliance costs, operational disruption, and risk disclosure of proprietary information.
Parents and caregivers: Mandatory cessation and disposal of suspected product could temporarily reduce local availability of formula and exacerbate short‑term supply shortages.
Based on analysis of 3 sections of legislative text.
Requires infant formula makers to notify FDA within one business day after a confirmed positive test for certain microorganisms, immediately consult with FDA, halt distribution and dispose of affected product as directed, and provide testing data and isolates (including genome data) for investigation. Directs FDA to respond quickly, confirm manufacturers’ investigations within 90 days, and give FDA new inspection/documentation authorities for compliance. Also directs FDA to produce multiple reports and quarterly supply-chain data for five years, coordinate with USDA and other agencies, and publish 1-, 3-, and 5‑year reports that identify evidence-based practices and recommended manufacturer changes to improve infant formula safety and resiliency of supply.